Skip to main content Skip to main menu
UF Health University of Florida
Department of Medicine College of Medicine – Jacksonville
Request an Appointment
Michael D Schweitzer Barrios

Michael D Schweitzer Barrios, M.D.

Assistant Professor

Department: Medicine – Jacksonville
Business Phone: (904) 244-8846
Business Email: michael.schweitzer@jax.ufl.edu

On This Page

About Michael D Schweitzer Barrios

Michael Schweitzer Barrios, M.D., is a University of Florida assistant professor of medicine and a pulmonologist and critical care medicine physician at UF Health in Jacksonville.

Additional Positions:
President
2025 – Current · Florida Thoracic Society (FTS)
Assistant Professor of Medicine
2023 – Current · University of Florida

Board Certifications

  • Critical Care Medicine
    American Board of Internal Medicine
  • Internal Medicine
    American Board of Internal Medicine
  • Pulmonary Medicine
    American Board of Internal Medicine

Clinical Profile

Specialties

  • General Internal Medicine

Subspecialties

  • Critical Care Medicine
  • Pulmonary Critical Care Medicine
  • Pulmonary Disease
  • Pulmonary Disease and Critical Care Medicine

Research Profile

Areas of Interest

  • Asthma
  • Biologics
  • Chronic obstructive pulmonary disease (COPD)

Publications

Academic Articles

Grants

  1. A Phase IIb Randomized, Double-blind, Placebo-controlled, Parallel, Multidose Study to Evaluate the Efficacy, Safety, and PK of AZD0292 in Participants 12 years of age and older with Bronchiectasis and Chronic Pseudomonas aeruginosa Colonization (CLEAR)

    Active

    Role:
    Principal Investigator
    Funding:
    ASTRAZENECA PHARM

  2. A Phase III, randomised, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of BI 1291583 2.5 mg administered once daily for up to 76 weeks in patients with bronchiectasis (The AIRTIVITY? Study)

    Active

    Role:
    Principal Investigator
    Funding:
    BOEHRINGER INGELHEIM INTL GmbH

  3. A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease

    Active

    Role:
    Principal Investigator
    Funding:
    ASTRAZENECA PHARM

  4. A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Investigate the Safety and Efficacy of Oral Brepocitinib in Adults with Cutaneous Sarcoidosis

    Active

    Role:
    Principal Investigator
    Funding:
    PRIOVANT THERAPEUTICS

  5. ICoN-1: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101 (Clofazimine Inhalation Suspension) When Added to Guideline-Based Therapy in Participants with Pulmonary Nontuberculous Mycobacterial Infection (Part A) Followed by an Open-Label Extension (Part B)

    Active

    Role:
    Principal Investigator
    Funding:
    ATLANTIC RESEARCH GROUP via MANNKIND

  6. myAirvo 3 (High Flow Nasal Therapy) for COPD patients in the home a multi-center randomized controlled trial

    Active

    Role:
    Principal Investigator
    Funding:
    TEMPLE UNIVERSITY via FISHER & PAYKEL HEALTHCARE

  7. A randomised, double-blind, parallel group, roll-over study evaluating long-term safety and efficacy of oral doses of BI 1291583 q.d. (Part A) followed by open label long-term safety assessment (Part B) in patients with bronchiectasis (ClairleafTM)

    Active

    Role:
    Principal Investigator
    Funding:
    BOEHRINGER INGELHEIM INTL GmbH

Contact Details

Phones:
Business:
(904) 244-8846
Emails:
Business:
michael.schweitzer@jax.ufl.edu
Addresses:
Business Street:
655 W 8TH ST
 JACKSONVILLE FL 32209